The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 3, 2012, Pages 381-384

  Hirai, Yoshimitsu ^a   Shimizu, Yukio ^a   Oura, Shoji ^a   Yoshimasu, Tatsuya ^a   Ota, Fuminori ^a   Nakamura, Rie ^a   Naito, Koma ^a   Nishiguchi, Haruka ^a   Hashimoto, Sayoko ^a   Okamura, Yoshitaka ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Histoculture drug response assay; Non small cell lung cancer; p53; Predictive factor; Ras mutation

Indexed keywords

CISPLATIN; K RAS PROTEIN; NAVELBINE; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; DRUG INHIBITION; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MUTATION; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

EID: 84861565104     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4): 351-360, 2004. (Pubitemid 38101630)
2. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B- III A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9): 719-727, 2006. (Pubitemid 44283661)
3. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352(25): 2589-2597, 2005. (Pubitemid 41007845)
4. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350(17): 1713-1721, 2004. (Pubitemid 38501140)
5. Tsao MS, Aviel-Ronen S, Ding K, et al: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25(33): 5240-5247, 2007. (Pubitemid 350232256)
6. Yoshimasu T, Oura S, Hirai I, et al: Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 133(2): 303-308, 2007. (Pubitemid 46136244)
7. Strauss GM, Herndon JE, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 22(14S): 621, 2004.
8. Douillard JY, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage I B-III A non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 7(9): 719-727, 2006. (Pubitemid 44283661)
9. Olaussen KA, Dunant A, Fouret P, et al: IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991, 2006. (Pubitemid 44343542)
10. Séve P, Lai R, Ding K, et al: Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13(3): 994-999, 2007. (Pubitemid 46340378)
11. Hirai Y, Yoshimasu T, Oura S, et al: Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer. Gan To Kagaku Ryoho 36(4): 611-614, 2009.
12. Hayashi Y, Kuriyama H, Umezu H, et al: Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small cell lung cancer. Intern Med 48(4): 203-208, 2009.
13. Hirai Y, Yoshimasu T, Oura S, et al: Is class III β-tubulin a true predictive marker for vinorelbine in non-small cell lung cancer ? Chemosensitivity data evidence. Anticancer Res 31(3): 999-1005, 2011.
14. Gunter VP, Waldrep JC, Guo JJ, et al: Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 30(9): 3557-3564, 2011.
15. Wang XW, Vermeulen W, Coursen JD, et al: The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10(10): 1219-1232, 1996. (Pubitemid 26171103)